R

Redx Pharma PLC
LSE:REDX

Watchlist Manager
Redx Pharma PLC
LSE:REDX
Watchlist
Price: 15 GBX 31.58% Market Closed
Market Cap: 50.2m GBX

Net Margin
Redx Pharma PLC

-789.1%
Current
-255%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-789.1%
=
Net Income
-33.2m
/
Revenue
4.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
UK
Redx Pharma PLC
LSE:REDX
50.2m GBP
-789%
US
Eli Lilly and Co
NYSE:LLY
770.2B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
404.9B USD
25%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
35%
CH
Roche Holding AG
SIX:ROG
206.2B CHF
14%
CH
Novartis AG
SIX:NOVN
179.7B CHF
25%
UK
AstraZeneca PLC
LSE:AZN
167.5B GBP
14%
US
Merck & Co Inc
NYSE:MRK
213.1B USD
27%
IE
Endo International PLC
LSE:0Y5F
183.8B USD
-126%
US
Pfizer Inc
NYSE:PFE
140.9B USD
13%

Redx Pharma PLC
Glance View

Market Cap
50.2m GBX
Industry
Pharmaceuticals

Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.

REDX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-789.1%
=
Net Income
-33.2m
/
Revenue
4.2m
What is the Net Margin of Redx Pharma PLC?

Based on Redx Pharma PLC's most recent financial statements, the company has Net Margin of -789.1%.

Back to Top